YKST02
/ Excyte
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 11, 2026
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=64 | Not yet recruiting | Sponsor: Excyte Biopharma Ltd
New P2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
May 12, 2026
A Study of YKST02 in Participants With Primary IgA Nephropathy
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting ➔ Recruiting
Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease
March 28, 2026
A Study of YKST02 in Participants With Primary IgA Nephropathy
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
New P1 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
April 07, 2026
Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Monotherapy • New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
August 28, 2024
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: Excyte Biopharma Ltd
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 5
Of
5
Go to page
1